HLA‐B*15 Is Associated With SARS‐CoV‐2 Infection in a Brazilian Population

Abstract

Studies have suggested an association between polymorphisms in class I genes of the major histocompatibility complex, specifically the human leukocyte antigen (HLA), and susceptibility to SARS‐CoV‐2. To explore this, 135 individuals with positive serological tests for SARS‐CoV‐2 were recruited. All the samples were collected before the advent of vaccines, avoiding immunization effects. Participants were divided into high and low neutralizing antibody titer groups, and polymorphisms in HLA‐A, HLA‐B, and HLA‐DRB1 genes were examined using PCR‐SSO. Allele prevalence in the study population was compared to the National Bone Marrow Volunteer Donors Register (REDOME) in São Paulo and between the high and low titer groups within the study population. Results indicated that the HLA‐B*15 polymorphism was more prevalent in the COVID‐19 positive group compared to the control population (COVID‐19 = 0.1370; Control = 0.0875; p = 0.0067). The HLA‐B*18 polymorphism was less prevalent in the COVID‐19 group (COVID‐19 = 0.0185; Control = 0.0534; p = 0.0064). Additionally, the HLA‐A*30 polymorphism was more prevalent in the high titer group within the (high = 0.10937; low = 0.02816; p = 0.0125). Other polymorphisms showed no significant differences. These findings align with international studies, suggesting these genes plays a role in COVID‐19 pathophysiology, however, further research is required to fully understand their impact.